The EDGE

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia OPEN

N C P Cross, H E White, D Colomer, H Ehrencrona, L Foroni, E Gottardi, T Lange, T Lion, K Machova Polakova, S Dulucq, G Martinelli, E Oppliger Leibundgut, N Pallisgaard, G Barbany, T Sacha, R Talmaci, B Izzo, G Saglio, F Pane, M C Müller and A Hochhaus

Leukemia 2015 29: 999-1003; advance online publication, February 5, 2015; 10.1038/leu.2015.29

MicroRNAs in B-cell lymphomas: how a complex biology gets more complex

K Musilova and M Mraz

Leukemia 2015 29: 1004-1017; advance online publication, December 26, 2014; 10.1038/leu.2014.351

Original Articles

ACUTE LEUKEMIAS

TGIF1 is a negative regulator of MLL-rearranged acute myeloid leukemia

A Willer, J S Jakobsen, E Ohlsson, N Rapin, J Waage, M Billing, L Bullinger, S Karlsson and B T Porse

Leukemia 2015 29: 1018-1031; advance online publication, October 28, 2014; 10.1038/leu.2014.307

Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice

A Staffas, C Karlsson, M Persson, L Palmqvist and M O Bergo

Leukemia 2015 29: 1032-1040; advance online publication, November 5, 2014; 10.1038/leu.2014.315

Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years

J J Cornelissen, J Versluis, J R Passweg, W L J van Putten, M G Manz, J Maertens, H B Beverloo, P J M Valk, M van Marwijk Kooy, P W Wijermans, M R Schaafsma, B J Biemond, M-C Vekemans, D A Breems, L F Verdonck, M F Fey, M Jongen-Lavrencic, J J W M Janssen, G Huls, J Kuball, T Pabst, C Graux, H C Schouten, A Gratwohl, E Vellenga, G Ossenkoppele and B Löwenberg on behalf of the HOVON and SAKK Leukemia Groups

Leukemia 2015 29: 1041-1050; advance online publication, November 27, 2014; 10.1038/leu.2014.332

A 3-microRNA scoring system for prognostication in de novo acute myeloid leukemia patients

M-K Chuang, Y-C Chiu, W-C Chou, H-A Hou, E Y Chuang and H-F Tien

Leukemia 2015 29: 1051-1059; advance online publication, November 27, 2014; 10.1038/leu.2014.333

Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial

J Schetelig, M Schaich, K Schäfer-Eckart, M Hänel, W E Aulitzky, H Einsele, N Schmitz, W Rösler, M Stelljes, C D Baldus, A D Ho, A Neubauer, H Serve, J Mayer, W E Berdel, B Mohr, U Oelschlägel, S Parmentier, C Röllig, M Kramer, U Platzbecker, T Illmer, C Thiede, M Bornhäuser and G Ehninger on behalf of the Study Alliance Leukemia (SAL)

Leukemia 2015 29: 1060-1068; advance online publication, December 1, 2014; 10.1038/leu.2014.335

A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia

S Piemontese, F Ciceri, M Labopin, A Bacigalupo, H Huang, S Santarone, N-C Gorin, Y Koc, D Wu, D Beelen, J Tischer, G Ehninger, W Arcese, A Nagler and M Mohty on behalf of Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT)

Leukemia 2015 29: 1069-1075; advance online publication, December 1, 2014; 10.1038/leu.2014.336

High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AML

A Jo, S Mitani, N Shiba, Y Hayashi, Y Hara, H Takahashi, I Tsukimoto, A Tawa, K Horibe, D Tomizawa, T Taga, S Adachi, T Yoshida and H Ichikawa

Leukemia 2015 29: 1076-1083; advance online publication, January 8, 2015; 10.1038/leu.2015.5

Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet

E Lengfelder, F Lo-Coco, L Ades, P Montesinos, D Grimwade, B Kishore, S M Ramadan, M Pagoni, M Breccia, A J G Huerta, A M Nloga, J D González-Sanmiguel, A Schmidt, J-F Lambert, S Lehmann, E Di Bona, B Cassinat, W-K Hofmann, D Görlich, M-C Sauerland, P Fenaux and M Sanz for the European LeukemiaNet

Leukemia 2015 29: 1084-1091; advance online publication, January 28, 2015; 10.1038/leu.2015.12

MYELODYSPLASIAS

Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells OPEN

H Dolatshad, A Pellagatti, M Fernandez-Mercado, B H Yip, L Malcovati, M Attwood, B Przychodzen, N Sahgal, A A Kanapin, H Lockstone, L Scifo, P Vandenberghe, E Papaemmanuil, C W J Smith, P J Campbell, S Ogawa, J P Maciejewski, M Cazzola, K I Savage and J Boultwood

Leukemia 2015 29: 1092-1103; advance online publication, November 27, 2014; 10.1038/leu.2014.331

CHRONIC MYELOPROLIFERATIVE NEOPLASIAS

PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation

A A Mian, A Rafiei, I Haberbosch, A Zeifman, I Titov, V Stroylov, A Metodieva, O Stroganov, F Novikov, B Brill, G Chilov, D Hoelzer, O G Ottmann and M Ruthardt

Leukemia 2015 29: 1104-1114; advance online publication, November 14, 2014; 10.1038/leu.2014.326

Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event

M Jawhar, J Schwaab, S Schnittger, K Sotlar, H-P Horny, G Metzgeroth, N Müller, S Schneider, N Naumann, C Walz, T Haferlach, P Valent, W-K Hofmann, N C P Cross, A Fabarius and A Reiter

Leukemia 2015 29: 1115-1122; advance online publication, January 8, 2015; 10.1038/leu.2015.4

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

L Kalmanti, S Saussele, M Lauseker, M C Müller, C T Dietz, L Heinrich, B Hanfstein, U Proetel, A Fabarius, S W Krause, S Rinaldetti, J Dengler, C Falge, E Oppliger-Leibundgut, A Burchert, A Neubauer, L Kanz, F Stegelmann, M Pfreundschuh, K Spiekermann, C Scheid, M Pfirrmann, A Hochhaus, J Hasford and R Hehlmann for the SAKK and the German CML Study-Group

Leukemia 2015 29: 1123-1132; advance online publication, February 13, 2015; 10.1038/leu.2015.36

CHRONIC LYMPHOCYTIC LEUKEMIA

The impact of SF3B1 mutations in CLL on the DNA-damage response

G D te Raa, I A M Derks, V Navrkalova, A Skowronska, P D Moerland, J van Laar, C Oldreive, H Monsuur, M Trbusek, J Malcikova, M Lodén, C H Geisler, J Hüllein, A Jethwa, T Zenz, S Pospisilova, T Stankovic, M H J van Oers, A P Kater and E Eldering

Leukemia 2015 29: 1133-1142; advance online publication, November 5, 2014; 10.1038/leu.2014.318

IMMUNOLOGY

Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation

L Crucitti, R Crocchiolo, C Toffalori, B Mazzi, R Greco, A Signori, F Sizzano, L Chiesa, E Zino, M T Lupo Stanghellini, A Assanelli, M G Carrabba, S Marktel, M Marcatti, C Bordignon, C Corti, M Bernardi, J Peccatori, C Bonini, K Fleischhauer, F Ciceri and L Vago

Leukemia 2015 29: 1143-1152; advance online publication, November 5, 2014; 10.1038/leu.2014.314

ONCOGENES, FUSION GENES AND TUMOR SUPPRESSOR GENES

Critical role of retinoid/rexinoid signaling in mediating transformation and therapeutic response of NUP98-RARG leukemia

J J Qiu, B B Zeisig, S Li, W Liu, H Chu, Y Song, A Giordano, J Schwaller, H Gronemeyer, S Dong and C W E So

Leukemia 2015 29: 1153-1162; advance online publication, December 16, 2014; 10.1038/leu.2014.334

LYMPHOMA

GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin’s B lymphomas via NF-κB-dependent induction of HIF-1α

J Chiche, S Pommier, M Beneteau, L Mondragón, O Meynet, B Zunino, A Mouchotte, E Verhoeyen, M Guyot, G Pagès, N Mounier, V Imbert, P Colosetti, D Goncalvès, S Marchetti, J Brière, M Carles, C Thieblemont and J-E Ricci

Leukemia 2015 29: 1163-1176; advance online publication, November 14, 2014; 10.1038/leu.2014.324

KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype

A Clipson, M Wang, L de Leval, M Ashton-Key, A Wotherspoon, G Vassiliou, N Bolli, C Grove, S Moody, L Escudero-Ibarz, G Gundem, K Brugger, X Xue, E Mi, A Bench, M Scott, H Liu, G Follows, E F Robles, J A Martinez-Climent, D Oscier, A J Watkins and M-Q Du

Leukemia 2015 29: 1177-1185; advance online publication, November 27, 2014; 10.1038/leu.2014.330

MYELOMA

Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential

T Paíno, B Paiva, J M Sayagués, I Mota, T Carvalheiro, L A Corchete, I Aires-Mejía, J J Pérez, M L Sanchez, P Barcena, E M Ocio, L San-Segundo, M E Sarasquete, R García-Sanz, M-B Vidriales, A Oriol, M-T Hernández, M-A Echeveste, A Paiva, J Blade, J-J Lahuerta, A Orfao, M-V Mateos, N C Gutiérrez and J F San-Miguel on behalf of the GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group

Leukemia 2015 29: 1186-1194; advance online publication, November 12, 2014; 10.1038/leu.2014.321

Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma OPEN

R Khan, S Apewokin, M Grazziutti, S Yaccoby, J Epstein, F van Rhee, A Rosenthal, S Waheed, S Usmani, S Atrash, S Kumar, A Hoering, J Crowley, J D Shaughnessy, Jr and B Barlogie

Leukemia 2015 29: 1195-1201; advance online publication, February 2, 2012; 10.1038/leu.2015.15

Letters to the Editor

PcG methylation of the HIST1 cluster defines an epigenetic marker of acute myeloid leukemia

G Tiberi, A Pekowska, C Oudin, A Ivey, A Autret, T Prebet, M Koubi, F Lembo, M-J Mozziconacci, G Bidaut, C Chabannon, D Grimwade, N Vey, S Spicuglia, B Calmels and E Duprez

Leukemia 2015 29: 1202-1206; advance online publication, December 8, 2014; 10.1038/leu.2014.339

Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia

D Rea, T Mirault, E Raffoux, N Boissel, A L Andreoli, P Rousselot, H Dombret and E Messas

Leukemia 2015 29: 1206-1209; advance online publication, December 8, 2014; 10.1038/leu.2014.342

CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis

M C Finazzi, A Carobbio, F Cervantes, I M Isola, A M Vannucchi, P Guglielmelli, A Rambaldi, G Finazzi, G Barosi and T Barbui

Leukemia 2015 29: 1209-1210; advance online publication, December 8, 2014; 10.1038/leu.2014.343

miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton’s tyrosine kinase inhibition with Ibrutinib

D Guinn, A S Ruppert, K Maddocks, S Jaglowski, A Gordon, T S Lin, R Larson, G Marcucci, E Hertlein, J Woyach, A J Johnson and J C Byrd

Leukemia 2015 29: 1210-1213; advance online publication, December 9, 2014; 10.1038/leu.2014.344

The IL-15 cytokine system provides growth and survival signals in Hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells

K Ullrich, F Blumenthal-Barby, B Lamprecht, K Köchert, D Lenze, M Hummel, S Mathas, B Dörken and M Janz

Leukemia 2015 29: 1213-1218; advance online publication, December 9, 2014; 10.1038/leu.2014.345

Biological properties of ligand-dependent activation of the MET receptor kinase in acute myeloid leukemia

S F McGee, S M Kornblau, Y Qiu, A T Look, N Zhang, S-Y Yoo, K R Coombes and A Kentsis

Leukemia 2015 29: 1218-1221; advance online publication, December 26, 2014; 10.1038/leu.2014.348

Corrigendum

ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia

M Zaliova, O Zimmermannova, P Dörge, C Eckert, A Möricke, M Zimmermann, J Stuchly, A Teigler-Schlegel, B Meissner, R Koehler, C R Bartram, L Karawajew, P Rhein, J Zuna, M Schrappe, G Cario and M Stanulla

Leukemia 2015 29: 1222; 10.1038/leu.2015.77